| Microorganism |
MIC50
(μg/ml) |
MIC90
(μg/ml) |
Range
(μg/ml) |
Antimicrobial |
Reference |
| Staphylococcus aureus (COL) |
- |
- |
45 － ? |
White wine  |
802 |
| Staphylococcus aureus (community-acquired + methicillin-resistant + USA400) |
- |
- |
0.75 － ? |
Erythromycin (E-mycin, Ery-tab, Benzamycin) |
1343 |
| Staphylococcus aureus (community-acquired + methicillin-resistant + USA400) |
- |
- |
1 － ? |
Vancomycin (Vancocyn, Lyphocin) |
1343 |
| Staphylococcus aureus (community-acquired + methicillin-resistant + USA400) |
- |
- |
2.9 － ? |
NSK5-15 |
1343 |
| Staphylococcus aureus (community-acquired + methicillin-resistant + USA400) |
- |
- |
5 － ? |
AM-165 |
1343 |
| Staphylococcus aureus (community-acquired + methicillin-resistant + USA400) |
- |
- |
9.6 － ? |
NSK4-77 |
1343 |
| Staphylococcus aureus (community-acquired + methicillin-resistant) |
0.06 |
0.25 |
0.06 － 0.25 |
Minocycline (Minocycline hydrochloride, Minocin) |
604 |
| Staphylococcus aureus (community-acquired + methicillin-resistant) |
0.12 |
0.12 |
0.06 － 0.12 |
Clindamycin (Cleocin) |
604 |
| Staphylococcus aureus (community-acquired + methicillin-resistant) |
0.12 |
0.12 |
0.06 － 0.12 |
Retapamulin |
604 |
| Staphylococcus aureus (community-acquired + methicillin-resistant) |
0.12 |
0.25 |
0.06 － 0.5 |
ME1036 |
110 |
| Staphylococcus aureus (community-acquired + methicillin-resistant) |
0.125 |
0.03 |
0.015 － 0.03 |
BC-7013 |
604 |
| Staphylococcus aureus (community-acquired + methicillin-resistant) |
0.25 |
0.25 |
0.12 － 0.25 |
Fusidic acid (Fucidin) |
604 |
| Staphylococcus aureus (community-acquired + methicillin-resistant) |
≤0.25 |
≤0.25 |
≤0.25 － ? |
Co-trimoxazole (Trimethoprim-sulfamethoxazole, TMP-SMX) |
110 |
| Staphylococcus aureus (community-acquired + methicillin-resistant) |
0.25 |
0.5 |
≤0.12 － >4 |
Levofloxacin (Levaquin, Quixin) |
110 |
| Staphylococcus aureus (community-acquired + methicillin-resistant) |
0.25 |
0.5 |
0.25 － 1 |
Daptomycin (Cubicin) |
110 |
| Staphylococcus aureus (community-acquired + methicillin-resistant) |
0.5 |
0.5 |
0.25 － 1 |
Ceftaroline |
110 |
| Staphylococcus aureus (community-acquired + methicillin-resistant) |
≤0.5 |
≤0.5 |
≤0.5 － >16 |
Tetracycline (Sumycin, Achromycin V, Steclin) |
110 |
| Staphylococcus aureus (community-acquired + methicillin-resistant) |
1 |
1 |
0.5 － 2 |
Vancomycin (Vancocyn, Lyphocin) |
110 |
| Staphylococcus aureus (community-acquired + methicillin-resistant) |
1 |
2 |
1 － 2 |
RWJ-416457 |
189 |
| Staphylococcus aureus (community-acquired + methicillin-resistant) |
2 |
2 |
≤0.5 － 8 |
Meropenem (Merrem) |
110 |
| Staphylococcus aureus (community-acquired + methicillin-resistant) |
2 |
2 |
1 － 2 |
Linezolid (PNU-100766, U-100766, Zyvox) |
110 |
| Staphylococcus aureus (community-acquired + methicillin-resistant) |
4 |
4 |
2 － 4 |
Linezolid (PNU-100766, U-100766, Zyvox) |
189 |
| Staphylococcus aureus (community-acquired + methicillin-resistant) |
≤4 |
≤4 |
≤4 － >128 |
Mupirocin (Bactroban) |
604 |
| Staphylococcus aureus (community-acquired + methicillin-resistant) |
>8 |
>8 |
2 － >8 |
Amoxicillin-clavulanate |
110 |
| Staphylococcus aureus (community-acquired + methicillin-resistant) |
>8 |
>8 |
2 － >8 |
Erythromycin (E-mycin, Ery-tab, Benzamycin) |
110 |
| Staphylococcus aureus (community-acquired + methicillin-resistant) |
>16 |
>16 |
>16 － ? |
Erythromycin (E-mycin, Ery-tab, Benzamycin) |
604 |
| Staphylococcus aureus (community-acquired + methicillin-resistant) |
>32 |
>32 |
16 － >32 |
Ceftriaxone (Rocephin) |
110 |
| Staphylococcus aureus (community-acquired + methicillin-resistant) |
109 |
109 |
≤1.7 － 129 |
Neomycin (Mycifradin, Neo-Fradin) |
604 |